Abstract:ObjectiveAberrant epigenetic remodeling represents a molecular hallmark in lung adenocarcinoma (LUAD). We aim to investigate the biological roles of SETDB2 and its underlying associations with oxidative stress, providing therapeutic targets for individualized treatment of LUAD. MethodsDifferential analysis was conducted via Limma package, and Kaplan-Meier analysis was performed with survival package. CCK-8, cell proliferation assay, transwell assay, and in vivo assays were conducted to assess the function of SETDB2. Western blot assay, RT-qPCR, and immunohistochemistry (IHC) were conducted to assess the expression levels of SETDB2/NRF2. Chromatin immunoprecipitation (ChIP) assay and ChIP-qPCR were conducted to assess the epigenetic roles of SETDB2. ResultsWe found that SETDB2 expression is decreased in tumor samples versus normal tissues in TCGA-LUAD cohort, LUAD-EAS cohort, GSE72094 dataset, and independent Soochow-LUAD dataset. Patients with low SETDB2 levels had a worse prognosis relative to those with high SETDB2. SETDB2 inhibition could significantly promote cell growth, migration ability, and stemness maintenance. Gene set enrichment analysis (GSEA) suggested that SETDB2 correlated with oxidative stress crosstalk and regulated NRF2 mRNA levels. ChIP assay suggested that SETDB2 mainly recruited the H3K9me3 enrichment at the NRF2 promoter region to suppress the mRNA levels of NRF2. Downregulated SETDB2 could activate NRF2 transcription and expression, thereby promoting its downstream targets, like NQO1, FTH1, and ME1. Functional experiments demonstrated that low SETDB2 allowed NRF2 to drive malignant processes of LUAD. SETDB2 overexpression attenuated the ability of NRF2 signaling to neutralize cellular reactive oxygen species (ROS) levels, leading to enhanced cell apoptosis. Overexpressed SETDB2 could inhibit tumor progression in vivo and further render LUAD cells sensitive to chemotherapy. ConclusionsIn conclusion, these findings uncovered the suppressive role of SETDB2 in LUAD. SETDB2 negatively regulates NRF2 signaling to modulate tumor progression, which creates a therapeutic vulnerability in LUAD.

Histone Methyltransferase SETD2: a Potential Tumor Suppressor in Solid Cancers

Setd2, A H3k36 Lysine Methyltransferase, is Essential for Adult Normal Hematopoiesis and Leukemia Stem Cells

Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma

The Role of Methyltransferase NSD2 As a Potential Oncogene in Human Solid Tumors

SETD2 in cancer: functions, molecular mechanisms, and therapeutic regimens

Targeting the Tumor Epigenetic Regulator SETDB1 for Tumor Therapy

Structure and function of the lysine methyltransferase SETD2 in cancer: From histones to cytoskeleton

Histone Methyltransferase SETD2 Modulates Alternative Splicing to Inhibit Intestinal Tumorigenesis.

Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.

Histone Methyltransferase SETD2 Inhibits Tumor Growth Via Suppressing CXCL1-mediated Activation of Cell Cycle in Lung Adenocarcinoma

Oncogene or Tumor Suppressor: The Coordinative Role of Lysine Methyltransferase SET7/9 in Cancer Development and the Related Mechanisms

Deficiency of Histone H3K36 Methyltransferase SETD2 Inhibits Proliferation and Migration of Hepatocellular Carcinoma Through ERK Pathway

Methyltransferase SETD2 Inhibits Tumor Growth and Metastasis via STAT1‐IL‐8 signaling mediated EMT in lung adenocarcinoma

Role of histone methyltransferase SETDB1 in regulation of tumourigenesis and immune response.

Setd2 is Critical for Maintaining Hematopoietic Homeostasis

Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1–IL‐8 signaling‐mediated epithelial–mesenchymal transition in lung adenocarcinoma

SETDB1, an H3K9-specific methyltransferase: An attractive epigenetic target to combat cancer

The function of histone methyltransferase SETDB1 and its roles in liver cancer

SETD2 Mediates Immunotherapy and Radiotherapy Efficacy Via Regulating DNA Damage Responses and Genomic Stability in Lung Adenocarcinoma

SETD2 Regulates Gene Transcription Patterns and is Associated with Radiosensitivity in Lung Adenocarcinoma

Histone Lysine Methyltransferase SETDB2 Suppresses NRF2 to Restrict Tumor Progression and Modulates Chemotherapy Sensitivity in Lung Adenocarcinoma